---
title: "MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295578877.md"
datetime: "2026-08-11T20:51:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295578877.md)
  - [en](https://longbridge.com/en/news/295578877.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295578877.md)
generator: "portal-rs"
---

# MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

Aug 11 (Reuters) - Gilead Sciences, Inc (GILD.O) : \* MACROGENICS - GILEAD SCIENCES EXERCISES OPTION FOR EXCLUSIVE LICENSE FOR A PRECLINICAL BISPECIFIC PROGRAM, TRIGGERS $10 MILLION PAYMENT TO MACROGENICS \* MACROGENICS - REMAINS ELIGIBLE TO RECEIVE UP TO APPROXIMATELY $1.6 BILLION IN ADDITIONAL DEVELOPMENT Source text: Further company coverage: (GILD.O)

### Related Stocks

- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [MGNX.US](https://longbridge.com/en/quote/MGNX.US.md)
- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)

## Related News & Research

- [Advisors Capital Management LLC Takes Position in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/296674916.md)
- [GSA Capital Partners LLP Takes Position in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/296193567.md)
- [Grandfield & Dodd LLC Makes New Investment in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/296196164.md)
- [European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status | GILD Stock News](https://longbridge.com/en/news/296773236.md)
- [MacroGenics SVP, GC and Secretary Jeffrey Stuart Peters disposes of 31,105 common shares for $129,086.75](https://longbridge.com/en/news/296541433.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**